NRAS and melanoma: Studies have shown that silencing ROCK1 via genetic modulation or inhibition with GSK269962A (a selective ROCK1 inhibitor) enhances the effectiveness of BRAF and MAPK inhibitors against BRAF and NRAS mutant melanoma cells [333].